A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 40
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
COMING SOON: End of March
2026 IOL Market Report: Global Analysis for 2025 to 2031, March, 2026
The “2026 IOL Market Report” delivers a comprehensive, data-driven view of the global intraocular lens market, combining detailed analysis of today’s landscape with five-year forecasts designed to inform strategy, investment, and competitive positioning.
Built on Market Scope’s proprietary models and deep industry insight, the report identifies the trends shaping demand, tracks shifts in technology adoption, and highlights the factors that will define success in an increasingly competitive and innovation-driven market.
The analysis segments the market across 11 distinct IOL categories—commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs— to provide a clear view of where growth is occurring and how the premium market continues to evolve.
In addition, the report profiles 40 leading companies, offering insight into their product portfolios, strategic positioning, competitive strengths, and future outlook to provide you with the intelligence needed to benchmark competitors and identify opportunities in the global IOL market.
Latest Industry News & Trends
3/27/2026
BreakingDealsRetina
Cencora to Acquire EyeSouth Partners’ Retina Business for $1.1 Billion
Cencora announced March 23 that it had agreed to acquire the retina business of EyeSouth Partners for $1.1 billion. The move follows Cencora’s $4.6 billion deal in January 2025 to buy Retina Consul...
3/27/2026
BreakingChinaDealsDry EyeRegulation
Regulators in China Approve Lotilaner Drops, Triggering $15 Million Payment to Tarsus
Tarsus Pharmaceuticals announced March 23 that regulators in China had approved TP-03 (lotilaner ophthalmic solution) 0.25%, its mite-killing treatment targeting Demodex blepharitis that is markete...
3/27/2026
BreakingGlaucomaLaserPresbyopiaRetinaRevenue
2025 Ophthalmic Revenue Roundup for Iridex and Lenz
Iridex, of Mountain View, California, reported March 26 that its 2025 revenue was $52.7 million, an 8 percent increase over $48.7 million in 2024. Cyclo G6 product revenue was $13.8 million, a 9 pe...
3/24/2026
ChinaCornealGlaucomaMeetingMyopiaNewsletter
2026 APAO Meeting in Hong Kong Attracts Surgeons from 111 Countries
Over 11 thousand eye care professionals met Feb. 4-7 in Hong Kong to exchange ideas and debate the strategies for managing eye diseases at the 2026 congress of the Asia-Pacific Academy of Ophthalmo...
3/27/2026
BreakingDeviceFundingIndustryPharma
J&J Continues to Reduce JLABS Footprint with Exit from New York
Johnson & Johnson is stepping away from its JLABS incubator site in New York, reducing its JLABS locations in the US to those in San Diego, San Francisco, and Boston. The New York site opened in 20...
3/27/2026
BreakingCataractDiagnosticFundusGlaucomaLaserRetinaSurgical
Zeiss Expands Clinical Ophthalmic and Optometric Device Portfolio in Canada
Carl Zeiss Meditec announced March 24 the addition of several advanced diagnostic, visualization, and therapeutic devices to its ophthalmic and optometric portfolio in Canada. Zeiss said its Clarus...
3/27/2026
BreakingChinaClinical TrialRetina
Innovent Reports Positive Phase III Results for Extended-Dosing Retinal Candidate
China’s Innovent Biologics reported March 23 that IBI302 (efdamrofusp alfa), its extended-dosing retinal candidate, met its primary visual acuity endpoint at week 52 in the Phase III STAR study. IB...
3/27/2026
BreakingCell TherapyCornealIndustry
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
Lineage Cell Therapeutics announced March 24 that it had expanded its cell transplant pipeline to include COR1, a corneal endothelial cell therapy candidate in preclinical development. Lineage, of ...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.